How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-covid-19-in-individuals-6-months-through-4-years-of-age.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of COVID-19 in individuals 6 months through 4 years of age — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of COVID-19 in individuals 6 months through 4 years of age (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of COVID-19 in individuals 6 months through 4 years of age, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg	bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg	Pfizer	mRNA vaccine	Spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 vaccine	BNT162b2 vaccine	Vaxxinity, Inc.	Not specified	Not specified
Investigational COVID-19 Vaccine	Investigational COVID-19 Vaccine	BioNTech	Not specified	Not specified
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	vaccine	SARS-CoV-2 spike protein
BNT162b2 (Omi KP.2)	bnt162b2-omi-kp-2	Pfizer Inc.	mRNA vaccine	Spike protein of SARS-CoV-2
BNT162b2 BA.4/5 bivalent	bnt162b2-ba-4-5-bivalent	Pfizer	mRNA vaccine	SARS-CoV-2 virus

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Prevention of COVID-19 in individuals 6 months through 4 years of age
BioNTech · 1 drug in Prevention of COVID-19 in individuals 6 months through 4 years of age
Pfizer Inc. · 1 drug in Prevention of COVID-19 in individuals 6 months through 4 years of age
Vaxxinity, Inc. · 1 drug in Prevention of COVID-19 in individuals 6 months through 4 years of age

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of COVID-19 in individuals 6 months through 4 years of age:

Cite this brief

Drug Landscape (2026). Prevention of COVID-19 in individuals 6 months through 4 years of age — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-covid-19-in-individuals-6-months-through-4-years-of-age. Accessed 2026-06-10.

Prevention of COVID-19 in individuals 6 months through 4 years of age full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing